Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial Study
Background: Growth hormone (GH) is a potential treatment in the assisted reproductive technology (ART) to improve endometrial receptivity and thickness. In the current study, we investigated the effect of the intrauterine administration of GH on the endometrial thickness (EMT) and ART outcomes in th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Royan Institute (ACECR), Tehran
2022-10-01
|
| Series: | International Journal of Fertility and Sterility |
| Subjects: | |
| Online Access: | https://www.ijfs.ir/article_249425_24841c764782ea87fd8d0716be79c567.pdf |
| _version_ | 1798029129298214912 |
|---|---|
| author | Soghra Hosseini Aghdam Alyeh Ghasemzadeh Laya Farzadi Kobra Hamdi Marayam Baradaran-Binazir Mohammad Nouri Amir Fattahi Ralf Dttrich |
| author_facet | Soghra Hosseini Aghdam Alyeh Ghasemzadeh Laya Farzadi Kobra Hamdi Marayam Baradaran-Binazir Mohammad Nouri Amir Fattahi Ralf Dttrich |
| author_sort | Soghra Hosseini Aghdam |
| collection | DOAJ |
| description | Background: Growth hormone (GH) is a potential treatment in the assisted reproductive technology (ART) to improve endometrial receptivity and thickness. In the current study, we investigated the effect of the intrauterine administration of GH on the endometrial thickness (EMT) and ART outcomes in the patients with refractory thin endometrium.Materials and Methods: In this clinical trial study, women with a refractory thin endometrium and a history of one or more frozen embryo transfer (FET) cancellation who were referred to the infertility center of the Tabriz Al-Zahra hospital (Tabriz, Iran) and Milad Infertility Clinic (Tabriz, Iran) received intrauterine injections of GH every other day from day 14 of the menstrual cycle until the EMT reached ≥7 mm in addition to the routine endometrium preparation protocol. EMT was evaluated during the treatment and in the cases with EMT ≥7 mm, biochemical/clinical pregnancy was evaluated after embryo transfer.Results: Thirty-one women aged 35.29 ± 6.21 years were included in this study. The mean amount of EMT was significantly increased following the GH treatment (7.03 ± 1.23 mm) vs. before treatment (5.14 ± 1.1 mm, P<0.001). The EMT reached ≥7 mm in the 65% patients (20/31). Also, the embryo transfer resulted in pregnancy in the patients, biochemical pregnancy: 9/20 (45%) and clinical pregnancy: 7/20 (35%). There was a positive correlation between EMT on the day 13 of cycle (before the treatment) and the maximum EMT (r=0.577 and P=0.001). The EMT was statistically different on the embryo transfer day between clinically pregnant and non-pregnant women (7.18 ± 0.56 vs. 6.21 ± 0.72 mm, P=0.007).Conclusion: The intrauterine administration of GH could be an appropriate therapeutic strategy for patients with refractory thin endometrium. This treatment could significantly increase the EMT as well as implantation and pregnancy rates in these patients (registration number: IRCT20210220050429N1). |
| first_indexed | 2024-04-11T19:20:18Z |
| format | Article |
| id | doaj.art-b5b2df9b236c45ad9646847f11573838 |
| institution | Directory Open Access Journal |
| issn | 2008-076X 2008-0778 |
| language | English |
| last_indexed | 2024-04-11T19:20:18Z |
| publishDate | 2022-10-01 |
| publisher | Royan Institute (ACECR), Tehran |
| record_format | Article |
| series | International Journal of Fertility and Sterility |
| spelling | doaj.art-b5b2df9b236c45ad9646847f115738382022-12-22T04:07:20ZengRoyan Institute (ACECR), TehranInternational Journal of Fertility and Sterility2008-076X2008-07782022-10-0116425125510.22074/ijfs.2022.541389.1210249425Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial StudySoghra Hosseini Aghdam0Alyeh Ghasemzadeh1Laya Farzadi2Kobra Hamdi3Marayam Baradaran-Binazir4Mohammad Nouri5Amir Fattahi6Ralf Dttrich7Women’s Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, IranWomen’s Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, IranWomen’s Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Gynecology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranCommunity Medicine Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Reproductive Biology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, IranWomen’s Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Obstetrics and Gynecology, Erlangen University Hospital, Friedrich-Alexander University of Erlangen–Nürnberg, Erlangen, GermanyBackground: Growth hormone (GH) is a potential treatment in the assisted reproductive technology (ART) to improve endometrial receptivity and thickness. In the current study, we investigated the effect of the intrauterine administration of GH on the endometrial thickness (EMT) and ART outcomes in the patients with refractory thin endometrium.Materials and Methods: In this clinical trial study, women with a refractory thin endometrium and a history of one or more frozen embryo transfer (FET) cancellation who were referred to the infertility center of the Tabriz Al-Zahra hospital (Tabriz, Iran) and Milad Infertility Clinic (Tabriz, Iran) received intrauterine injections of GH every other day from day 14 of the menstrual cycle until the EMT reached ≥7 mm in addition to the routine endometrium preparation protocol. EMT was evaluated during the treatment and in the cases with EMT ≥7 mm, biochemical/clinical pregnancy was evaluated after embryo transfer.Results: Thirty-one women aged 35.29 ± 6.21 years were included in this study. The mean amount of EMT was significantly increased following the GH treatment (7.03 ± 1.23 mm) vs. before treatment (5.14 ± 1.1 mm, P<0.001). The EMT reached ≥7 mm in the 65% patients (20/31). Also, the embryo transfer resulted in pregnancy in the patients, biochemical pregnancy: 9/20 (45%) and clinical pregnancy: 7/20 (35%). There was a positive correlation between EMT on the day 13 of cycle (before the treatment) and the maximum EMT (r=0.577 and P=0.001). The EMT was statistically different on the embryo transfer day between clinically pregnant and non-pregnant women (7.18 ± 0.56 vs. 6.21 ± 0.72 mm, P=0.007).Conclusion: The intrauterine administration of GH could be an appropriate therapeutic strategy for patients with refractory thin endometrium. This treatment could significantly increase the EMT as well as implantation and pregnancy rates in these patients (registration number: IRCT20210220050429N1).https://www.ijfs.ir/article_249425_24841c764782ea87fd8d0716be79c567.pdfthin endometriumpregnancyimplantationartgrowth hormone |
| spellingShingle | Soghra Hosseini Aghdam Alyeh Ghasemzadeh Laya Farzadi Kobra Hamdi Marayam Baradaran-Binazir Mohammad Nouri Amir Fattahi Ralf Dttrich Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial Study International Journal of Fertility and Sterility thin endometrium pregnancy implantation art growth hormone |
| title | Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial Study |
| title_full | Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial Study |
| title_fullStr | Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial Study |
| title_full_unstemmed | Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial Study |
| title_short | Growth Hormone: A Potential Treatment of Patients with Refractory Thin Endometrium: A Clinical Trial Study |
| title_sort | growth hormone a potential treatment of patients with refractory thin endometrium a clinical trial study |
| topic | thin endometrium pregnancy implantation art growth hormone |
| url | https://www.ijfs.ir/article_249425_24841c764782ea87fd8d0716be79c567.pdf |
| work_keys_str_mv | AT soghrahosseiniaghdam growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy AT alyehghasemzadeh growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy AT layafarzadi growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy AT kobrahamdi growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy AT marayambaradaranbinazir growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy AT mohammadnouri growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy AT amirfattahi growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy AT ralfdttrich growthhormoneapotentialtreatmentofpatientswithrefractorythinendometriumaclinicaltrialstudy |